| Schedule of Income (Loss) Per Share, Basic and Diluted |
The following table sets forth the computation of net income (loss) per share for the periods presented:
| | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | Nine Months Ended March 31, | (in thousands, except per share amounts) | 2024 | | 2023 | | 2024 | | 2023 | | Basic: | | | | | | | | | Numerator: | | | | | | | | Net income (loss) attributable to common shareholders | $ | 8,551 | | | $ | 9,264 | | | $ | (3,108) | | | $ | (10,706) | | | | | | | | | | | | | | | | | | | | | | | | | | | Denominator: | | | | | | | | | Weighted-average common stock outstanding | 169,070 | | | 166,543 | | | 168,291 | | | 165,951 | | Net income (loss) per share—basic: | $ | 0.05 | | | $ | 0.06 | | | $ | (0.02) | | | $ | (0.06) | | | Diluted: | | | | | | | | | Numerator: | | | | | | | | Net income (loss) attributable to common and common equivalent shareholders | $ | 8,551 | | | $ | 9,264 | | | $ | (3,108) | | | $ | (10,706) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Denominator: | | | | | | | | | Weighted-average common stock outstanding | 169,070 | | | 166,543 | | | 168,291 | | | 165,951 | | | | | | | | | | | | | | | | | | Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP(1) | 1,886 | | | 1,362 | | | — | | | — | | | | | | | | | | | Total common and common equivalent shares outstanding | 170,956 | | | 167,905 | | | 168,291 | | | 165,951 | | Net income (loss) per share—diluted: | $ | 0.05 | | | $ | 0.06 | | | $ | (0.02) | | | $ | (0.06) | |
(1) Excluded from the computation of net income (loss) per share-diluted for the nine months ended March 31, 2024 and 2023, because the effect would have been anti-dilutive.
|
| Schedule of Antidilutive Securities Excluded from Computation of Income (Loss) Per Share |
The weighted average potential shares of common stock that were excluded from the calculation of net income (loss) per share-diluted because including them would have been anti-dilutive are as follows for the periods presented:
| | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | Nine Months Ended March 31, | | (in thousands) | 2024 | | 2023 | | 2024 | | 2023 | | | | | | | | | | | | | | | | | | | | | | | | | | Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP | 6,483 | | | 4,181 | | | 12,145 | | | 8,338 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
The weighted average potential shares of common stock that were excluded from the calculation of net income (loss) per share-diluted because the performance or market conditions associated with these awards were not met are as follows for the periods presented:
| | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | Nine Months Ended March 31, | | (in thousands) | 2024 | | 2023 | | 2024 | | 2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Shares subject to outstanding PVU’s | 6,244 | | | 4,100 | | | 6,268 | | | 4,158 | | | Shares subject to outstanding PSU's | — | | | 10 | | | — | | | 7 | | | Total | 6,244 | | | 4,110 | | | 6,268 | | | 4,165 | |
|